Cerebral adrenoleukodystrophy represents the most devastating phenotypic manifestation of X-linked adrenoleukodystrophy, presenting with severe, rapidly advancing neuroinflammation. While pediatric natural history is relatively well characterized, adult cerebral adrenoleukodystrophy presents unique diagnostic and therapeutic challenges for clinicians. Historically, adult onset forms have been understudied due to disease rarity and variable phenotypic presentation. Consequently, neurologists often face uncertainty when determining optimal monitoring intervals and intervention timelines. In adult patients, therapeutic options remain largely restricted to allogeneic hematopoietic stem cell transplantation, a procedure that carries substantial morbidity and treatment-related mortality. Therefore, establishing precise, objective markers of disease progression is vital to optimize clinical outcomes and balance treatment risks. A groundbreaking multicenter study published in Neurology now offers critical longitudinal insights into how cerebral demyelinating lesions expand in affected adult males.

Understanding Adult Cerebral Adrenoleukodystrophy and Clinical Challenges

Adult cerebral adrenoleukodystrophy arises from mutations in the ABCD1 gene, leading to impaired peroxisomal beta-oxidation of very long-chain fatty acids. Consequently, toxic accumulation of these fatty acids triggers catastrophic neuroinflammatory demyelination within the central nervous system. In adult men, the disease frequently superimposes upon a pre-existing adrenomyeloneuropathy phenotype, complicating early recognition. Furthermore, clinical progression in adults can be intensely heterogeneous, ranging from indolent white matter changes to rapidly fatal neurodegeneration.

Because hematopoietic stem cell transplantation can only halt disease progression when administered during early stages, timely identification of rapid progressors is paramount. However, standard clinical examinations often fail to capture active neuroaxonal loss until substantial neurological disability occurs. Historically, clinicians relied heavily on the semiquantitative Loes MRI score, which was originally developed for pediatric cohorts. Although the Loes score provides a standardized overview of anatomical involvement, it often lacks the sensitivity required to detect subtle volumetric changes in adult white matter lesions. As a result, neurologists have urgently needed longitudinal quantitative imaging tools to accurately forecast disease trajectory and guide high-stakes therapeutic decisions.

Volumetric AI Segmentation and Multicenter Study Design

To address these critical knowledge gaps, researchers conducted a comprehensive multicenter retrospective cohort study across three major leukodystrophy centers. The investigators analyzed adult male patients with genetically confirmed X-linked adrenoleukodystrophy between 2000 and 2025. Specifically, inclusion required patients to have documented lesion progression across at least two high-quality MRI scans with a minimum untreated follow-up period of three months.

To overcome the limitations of manual slice-by-slice tracing, the team utilized an advanced 3D U-Net convolutional neural network for automated lesion segmentation. Subsequently, expert neuroradiologists performed rigorous manual corrections to ensure maximal anatomical accuracy. This robust machine learning pipeline analyzed 338 longitudinal MRI scans from 48 eligible adult patients out of 578 screened individuals. In addition to volumetric segmentation, the investigators evaluated gadolinium contrast enhancement, primary lesion location, and serum neurofilament light chain concentrations. By standardizing quantitative volumetric metrics across multiple international tertiary centers, the study established an unprecedented longitudinal dataset of untreated adult cerebral lesion kinetics.

Exponential Lesion Growth Rates and Contrast Enhancement Dynamics

The study revealed that cerebral demyelinating lesions in adult patients expand at an overall exponential growth rate of 3.4% per month. However, the researchers observed marked interindividual variability, with monthly volumetric growth rates ranging widely from 0.5% to 7.3%. This wide spectrum explains why some adult patients experience rapid cognitive and motor deterioration while others remain clinically stable for extended periods.

Importantly, the presence of active gadolinium contrast enhancement emerged as a pivotal determinant of lesion kinetics. Lesions demonstrating active contrast enhancement expanded significantly faster than non-enhancing lesions, exhibiting a growth rate of 3.4% per month compared to just 0.9% per month in non-enhancing lesions. Consequently, blood-brain barrier disruption directly correlates with rapid inflammatory expansion. Furthermore, the initial anatomical location of the primary lesion strongly influenced overall expansion velocity. Lesions originating in the splenium of the corpus callosum and parieto-occipital white matter displayed distinct kinetic profiles compared to frontal or projection fiber lesions. Therefore, multimodal MRI assessment including contrast dynamics provides essential prognostic stratification.

Serum Neurofilament Light Chain as a Quantitative Biomarker

Beyond advanced neuroimaging, the researchers evaluated serum neurofilament light chain as a minimally invasive fluid biomarker of ongoing neuroaxonal injury. Notably, elevated serum neurofilament light chain concentrations correlated robustly with active cerebral lesion dynamics in adult patients. Furthermore, statistical modeling demonstrated that absolute lesion volume and monthly volumetric lesion increase explained circulating neurofilament levels far better than semiquantitative Loes scores.

Specifically, models incorporating absolute lesion volume and growth rate achieved an adjusted coefficient of determination of 0.669. In contrast, models based solely on semiquantitative Loes score metrics yielded an adjusted coefficient of determination of only 0.488. This critical finding indicates that blood-based neurofilament measurements reflect real-time active tissue destruction rather than static structural damage. Consequently, serial serum neurofilament monitoring offers a practical, highly sensitive tool that can complement routine neuroimaging. By integrating regular biomarker sampling into routine outpatient protocols, clinicians can readily identify subclinical disease acceleration before overt clinical deterioration occurs.

Clinical Implications for Patient Selection and Therapeutic Monitoring

These quantitative insights carry profound clinical implications for managing adult patients facing complex decisions regarding hematopoietic stem cell transplantation. Because allogeneic transplantation carries substantial risks of graft-versus-host disease and transplant-related mortality, careful patient selection is imperative. Clinicians must accurately distinguish patients with rapidly progressive inflammatory demyelination from those with indolent, non-inflammatory disease courses.

By demonstrating that exponential lesion growth, active gadolinium enhancement, and elevated serum neurofilament levels identify high-risk phenotypes, this study provides an objective framework for risk stratification. Patients displaying rapid volumetric expansion and high neurofilament levels may derive the greatest benefit from early transplant consideration before irreversible cognitive decline sets in. Conversely, patients with non-enhancing lesions and slow growth rates might avoid unnecessary treatment toxicity under rigorous active surveillance. In addition, these quantitative volumetric endpoints will serve as sensitive, objective outcome measures for future clinical trials evaluating novel gene therapies and small-molecule neuroprotective agents.

Frequently Asked Questions

What is the typical lesion growth rate in adult cerebral adrenoleukodystrophy?

Lesions in adult cerebral adrenoleukodystrophy expand at an average exponential rate of 3.4% per month. However, growth rates vary substantially among individuals, ranging between 0.5% and 7.3% monthly. This marked variability highlights why personalized volumetric monitoring is crucial for accurate prognostic evaluation.

Why does gadolinium contrast enhancement matter in lesion progression?

Active gadolinium contrast enhancement indicates active blood-brain barrier disruption and intense neuroinflammation. Enhancing lesions progress nearly four times faster than non-enhancing lesions, expanding at 3.4% per month compared to 0.9% per month, making contrast status a critical determinant of clinical urgency.

How does serum neurofilament light chain assist disease management?

Serum neurofilament light chain serves as a sensitive blood biomarker reflecting active neuroaxonal damage. Circulating levels correlate strongly with absolute lesion volume and monthly expansion rates, allowing clinicians to detect subclinical disease progression more accurately than traditional semiquantitative scoring systems.

Disclaimer: This content is for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read in this article. If you think you may have a medical emergency, call your doctor or emergency services immediately. Reliance on any information provided by this article is solely at your own risk. Refer to the latest local and national guidelines for clinical practice.

References

1. Ponleitner M et al. Analysis of Interindividual Lesion Progression Variability in Adult Cerebral Adrenoleukodystrophy. Neurology. 2026 Sep 08. doi: 10.1212/WNL.0000000000218407. PMID: 42585611.
2. Engelen M, van Ballegoij WJC, Mallack EJ, et al. X-linked adrenoleukodystrophy: Clinical presentation and guidelines for diagnosis, follow-up and management. Neuropediatrics. 2021;52(4):252-264.
3. Turk BR, Theda C, Fatemi A, Moser AB. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Mol Sci. 2020;21(1):217.